FDA Approves Aducanumab for Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) today approved aducanumab (Biogen/Eisai) to treat Alzheimer’s disease.

This is the first drug that slows Alzheimer’s disease. And, this is the beginning of a completely new future for Alzheimer’s treatments. This is a new type of Alzheimer’s treatment; it addresses the disease in a way that has never been done before, compared to currently approved drugs.

Alzheimer’s — a progressive, degenerative and fatal brain disease — is the most common cause of dementia. For Alzheimer’s Disease Facts and Figures, an annual report by the Alzheimer’s Association, visit alz.org/facts.

Harry Johns, Alzheimer’s Association president and CEO said “On behalf of those impacted by Alzheimer’s and all other dementia, the Alzheimer’s Association welcomes and celebrates today’s historic FDA approval of aducanumab for Alzheimer’s disease. This approval is a victory for people living with Alzheimer’s and their families.

“It is a new day. This approval allows people living with Alzheimer’s more time to live better. For families it means being able to hold on to their loved ones longer. It is about reinvigorating scientists and companies in the fight against this scourge of a disease. It is about hope.”